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Abstract 
Background: Patients with Idiopathic membranous nephropathy (IMN) have various outcomes. The aim of this study 
is to construct a tool for clinicians to precisely predict outcome of IMN.
Methods: IMN patients diagnosed by renal biopsy from Shanghai Ruijin Hospital from 2009.01 to 2013.12 were 
enrolled in this study. Primary outcome was defined as a combination of renal function progression [defined as a 
reduction of estimated glomerular filtration rate (eGFR) equal to or over 30% comparing to baseline], ESRD or death. 
Risk models were established by Cox proportional hazard regression analysis and validated by bootstrap resampling 
analysis. ROC curve was applied to test the performance of risk score.
Results: Totally 439 patients were recruited in this study. The median follow-up time was 38.73 ± 19.35 months. 
The enrolled patients were 56 (15–83) years old with a male predominance (sex ratio: male vs female, 1:0.91). The 
median baseline serum albumin, eGFR-EPI and proteinuria were 23(8–43) g/l, 100.31(12.81–155.98) ml/min/1.73 m2 
and 3.98(1.50–22.98) g/24 h, respectively. In total, there were 36 primary outcomes occurred. By Cox regression 
analysis, the best risk model included age [HR: 1.04(1.003–1.08), 95% CI from bootstrapping: 1.01–1.08), eGFR [HR: 
0.97 (0.96–0.99), 95% CI from bootstrapping: 0.96–0.99) and proteinuria [HR: 1.09 (1.01–1.18), 95% CI from bootstrap-
ping: 1.02–1.16). One unit increasing of the risk score based on the best model was associated with 2.57 (1.97–3.36) 
fold increased risk of combined outcome. The discrimination of this risk score was excellent in predicting combined 
outcome [C statistics: 0.83, 95% CI 0.76–0.90].
Conclusions: Our study indicated that older IMN patients with lower eGFR and heavier proteinuria at the time of 
renal biopsy were at a higher risk for adverse outcomes. A risk score based on these three variables provides clinicians 
with an effective tool for risk stratification.
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Background
Idiopathic membranous nephropathy (IMN) is one of the 
most common types of adult-onset primary glomerulo-
nephritis [1–3]. The incidence of IMN has increased dra-
matically recently at least in China [2, 4, 5] which maybe 
partly due to air pollution for example the increased level 
of PM2.5 in the air [5]. IMN is an immune complex-
mediated glomerular disease. The understanding of the 
pathophysiological mechanism underlying IMN has been 
greatly improved thanks to the discovery of anti-PLA2R 
and anti-THSD7A antibodies in IMN patients [6, 7]. 
Interestingly, previous studies [8–10] based on western 
population have shown that the level of anti-PLA2R anti-
body in serum was helpful in the differential diagnosis 
and the prognosis prediction.
It was reported that approximately one-third of all 
IMN patients will develop end stage renal disease 
(ESRD). Both clinical variables including age, gender, 
serum creatinine, proteinuria and histological variables 
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including tubulointerstitial fibrosis and focal segmental 
sclerosis(FSGS) at time of diagnosis were associated with 
renal function progression in IMN patients based on 
prior studies [11, 12]. However, Trayanov et al. [13] failed 
to validate the correlation between FSGS and progres-
sive renal disease. Zent et al. [14] found that elderly and 
young patients had similar rates of ESRD (12% vs 18%, 
P > 0.05) based on a cohort of 323 IMN patients. The dis-
crepant findings suggested validating studies were nec-
essary in independent cohorts with diverse populations 
since most of these studies were performed in Western 
countries. Finally, establishing a risk model to combine 
the independent predictors could potentially improve 
the accuracy of prediction since the effect of each single 
predictor is relatively small. In this study, we enrolled an 
extended Chinese IMN cohort to establish a risk score 
to precisely predict the outcome of these patients. This 
prediction tool will be helpful to clinicians for assess-
ing the risk classification of IMN patients and to decide 
who need more aggressive treatments and more frequent 
follow-up.
Methods
Study population and study design
All the patients in this study were recruited at Shang-
hai Ruijin Hospital from 2009.01 to 2013.12. The inclu-
sion criteria were as follows: (1) renal biopsy was 
required for the diagnosis of IMN; (2) age ≥ 15 years; (3) 
informed consent was obtained. The exclusion criteria 
were: (1) patients with secondary causes of membranous 
nephropathy, such as malignancy, autoimmune disease 
and hepatitis B. (2) Patients receiving immunosuppres-
sive treatment before hospitalization in our nephrology 
service. (3) Patients with severe heart failure or hepatic 
failure.
The primary outcome was defined as a combination of 
renal function progression, ESRD or death. Renal func-
tion progression was defined as a reduction in eGFR 
greater than or equal to 30% compared with renal func-
tion at the time of renal biopsy [15]. ESRD was defined as 
the need for dialysis or kidney transplant.
Data collection
The patients’ demographic characteristics, baseline and 
follow-up clinical data were collected. eGFR was calcu-
lated by eGFR-EPI formula [16]. Renal biopsies were 
evaluated and scored by 2 experienced nephropatholo-
gists. The IMN stages was assessed based on the criteria 
listed below. Pathological staging oF IMN [17].
Stage I: Normal glomerule under light microscope 
(LM) with subepithelial immune complex depos-
its under electronic microscope (EM). Stage II: 
Heterogenous thickening of glomerular basement 
membrane (GBM) with formation of spikes under LM 
and subepithelial immune complex deposits under 
EM. Stage III: Evident thickening of GBM under LM. 
Either deposition of immune complex in the subepi-
thelial space or in GBM is observed under EM. Stage 
IV: Evident thickening of GBM under LM. Thick GBM 
with absorption of immune complex is observed under 
EM. Severe interstitial fibrosis was defined as superior 
to 50% interstitial fibrosis. Serum PLA2R antibodies 
were measured by an ELISA test (Euroimmun, Lübeck, 
Germany) in patients whose serum was available at the 
time of renal biopsy. Glomerular PLA2R deposits were 
measured by using an indirect immunofluorescence test 
with anti-PLA2R antibody (Atlas Antibodies AB, Stock-
holm, Sweden). IgG subclasses were tested by direct 
immunofluorescence methods with mouse anti-human 
IgG1 FITC, anti-human IgG2 FITC, anti-human IgG3 
FITC and anti-human IgG4 FITC (Southern Biotech, 
CAT. No 9200-02; Southern Biotech, CAT. No9080-02; 
Southern Biotech, CAT. No 9052-02; Southern Biotech, 
CAT. No 9210-02). PLA2R staining and IgG subclasses 
were evaluated by pathologists with standard immu-
nofluorescence microscopy. The presence of granular 
capillary loop staining in the glomeruli was defined as 
positive.
Statistical analysis
Continuous variables that were normally distributed 
were expressed as the mean ± SD and compared with 
Student’s t-test. Continuous variables that had a skewed 
distribution were presented as the median (Range) and 
compared with the Mann–Whitney U test. Categorical 
variables were compared with the Chi squared test. The 
proportional hazard assumption was checked by test-
ing covariate-by-time interactions for each variable. 
The Cox proportional hazards models were built to 
test the associations between the variables and the out-
comes. The best model was selected using a stepwise 
selection of variables using Akaike information selec-
tion criterion. Variables with P values less than 0.05 in 
the univariate analysis were included in the multivari-
ate Cox proportional hazards models. A nonparametric 
bootstrapping resampling analysis with replacements 
was used to validate the risk factors obtained in mul-
tivariate Cox analysis. Only the independent predic-
tors validated by bootstrapping resampling analysis 
were retained in the final model for the calculation of 
risk score. ROC curve were generated to compare the 
discrimination among the risk factors and risk scores. 
Two sided P value < 0.05 was considered statistically 
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significant. The statistical analysis was performed 
with IBM SPSS (version 21.0, Chicago, IL, USA) and R 
software.
Results
Baseline demographic and clinical data
In total, 439 patients were recruited. The baseline char-
acteristics of the enrolled patients are listed in Table  1. 
The median age of all the enrolled patients was 56 (15–
83) years old with a male predominance sex ratio: male 
vs female was 1:0.91. Among all patients, baseline serum 
albumin was 23(8–43) g/l, eGFR was 100.31(12.81–
155.98) ml/min/1.73  m2 and proteinuria was 3.98(1.50–
22.98) g/24 h. Serum PLA2R antibody was measured in 
130 patients with a median titer of 26.54 (0.52–1040.18) 
RU/L. A total of 59.91% of the patients were diagnosed 
as stages II IMN, 19.36% I IMN, 20.05% III IMN and 
0.68% IV IMN (Additional file 1: Table S1). Compared to 
patients in other stages, patients in stage IV had heavier 
proteinuria, lower albumin and worse renal function 
at diagnosis. Severe tubulointerstitial lesions(account 
for ≥ 50%) were detected in 3.42% patients at the time of 
diagnosis. Renal PLA2R staining was positive in 85.11% 
patients. Of all patients with IgG subclasses testing, 
84.82% were IgG1 positive, 58.04% IgG2 positive, 23.21% 
IgG3 positive, and 92.86% were IgG4 positive. During a 
median follow-up of 38.73 ± 19.35  months, 36 patients 
(8.20%) had primary events of which there were 24 
(5.47%) renal function progression, 3 (0.68%) ESRD and 9 
(2.05%) death (Table 1 and Fig. 1a). 
Identification of risk factors and establishing risk scores
The proportional hazard assumption was checked by 
testing covariate-by-time interactions for each variable 
(Additional file  1: Table  S2) showing all these variables 
agreed with proportional hazard assumption. In the uni-
variate analysis, age, serum albumin, proteinuria, eGFR 
and severe interstitial fibrosis were associated with pri-
mary outcomes. In multivariate analysis, the best model 
included age (HR: 1.04, 95% CI 1.003–1.08, P = 0.04, 95% 
CI from bootstrapping: 1.01–1.08), eGFR-EPI (HR: 0.97, 
95% CI 0.96–0.99, P < 0.01, 95% CI from bootstrapping: 
0.96–0.99) and proteinuria (HR: 1.09, 95% CI 1.01–1.18, 
P = 0.03, 95% CI from bootstrapping: 1.02 ~ 1.16). A 
risk score based on the regression coefficients of these 
3 risk factors was then developed: Risk score = 0.04*Age 
(years) − 0.03*eGFR-EPI (ml/min/1.73  m2) + 0.09* pro-
teinuria (g/24  h). Each unit increasing in the risk score 
was associated with a 2.57 (1.97–3.36) fold increasing in 
the risk of primary outcome occurrence (Table 2).
Assessment of the risk score performance
The ROC curve was generated to compare the prognostic 
values of the identified risk factors with the risk scores. 
The risk score (C statistics: 0.83, 95% CI 0.76–0.90) 
was better than each of the 3 risk factors alone includ-
ing age(C statistics: 0.79, 95% CI 0.72–0.86), eGFR-EPI 
(C statistics: 0.81, 95% CI 0.73–0.89) and proteinuria (C 
statistics: 0.69, 95% CI 0.61–0.77), which suggested that 
the risk score was had better discrimination in predict-
ing adverse outcomes in IMN patients (Fig. 2a). Besides, 
we compared the predicted risk versus observed rate of 
primary outcome. The discriminative slope was calcu-
lated as the difference between the mean predicted prob-
ability between IMN patients with or without primary 
outcome (1.80) indicating good performance of the risk 
score (Fig. 2b). Next we divided the patients into 2 groups 
based on median of risk scores at − 0.29. A Kaplan–
Meier curve revealed that the patients in the high risk 
subgroup had a 5.97-fold increased risk for developing 
primary outcomes (HR: 5.97, 95% CI 2.32–15.35) com-
pared with patients in the low risk subgroup (Fig. 2c).
Associations between serum PLA2R antibody, renal PLA2R 
staining and primary outcome
There was no significant difference in serum PLA2R 
antibody titer (30.40 RU/L vs 12.17 RU/L, P = 0.09) and 
Table 1 Baseline characteristics of IMN patients
Continuous variables presented as mean ± SD or median (range)
ESRD end-stage renal disease, LM light microscopic, IF immunofluorescence
a Renal progression: a reduction in eGFR greater than or equal to 30% compared 
with that at renal biopsy
All
Follow-up time (m) 38.73 ± 19.35
Age (years) 56 (15–83)
Female (%) 209 (47.61%)
Albumin (g/l) 23 (8–43)
Proteinuria (g/24 h) 3.98 (1.5–22.98)
eGFR (ml/min/1.73 m2) 100.31 (12.81–155.98)
Microscopic hematuria (%) 260 (59.22%)
Triglyceride (mmol/l) 2.35 (0.70–10.92)
Cholesterol (mmol/l) 7.17 (1.84–16.71)
Uric acid (μmol/l) 357.03 ± 83.38
Serum PLA2R antibody (RU/l) 26.54 (0.52–1040.18)
Pathology
 LM-stages I and II (%) 348 (79.27%)
 LM- ≥ 50% tubulointerstitial lesions (%) 15 (3.42%)
 IF-PLA2R positive staining (%) 80/94 (85.11%)
 IF-IgG1 positive (%) 95/112 (84.82%)
 IF-IgG4 positive (%) 104/112 (92.86%)
 Primary outcomes (%) 36 (8.20%)
 Renal function progression (%)a 24 (5.47%)
 Death (%) 9 (2.05%)
 ESRD (%) 3 (0.68%)
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renal PLA2R positive staining (100% vs 84.27%, P = 1.00) 
between patients with or without primary outcome 
occurrences. Then, the patients were divided evenly into 
two groups (high vs low serum PLA2R antibody groups) 
based on median serum PLA2R antibody titers. A 
Kaplan–Meier curve revealed a similar tendency toward 
primary outcomes in the two groups (P = 0.19). No sig-
nificant difference was observed in the occurrence of pri-
mary outcomes in patients with positive or negative renal 
PLA2R staining.
Discussion
The disease course of IMN is quite variable. An effective 
tool for clinicians to decide which patients need more 
aggressive therapy and more frequent follow-up would 
be helpful in clinical practice. However, the risk factors 
reported by previous studies [11, 12] are still controver-
sial, and there is no well-established consensus. Besides, 
most of the studies were conducted in western countries 
and needed to be validated in other populations, such 
as Asian populations. Thus, our study has explored the 
a b
c d
Fig. 1 Survival curves for primary outcomes a in all IMN patients (n = 439): primary outcome-free time: 38.73 ± 19.35 months; b Solid lines: 
eGFR-EPI < 60 ml/min*1.73 m2, dashed lines: eGFR-EPI ≥ 60 ml/min*1.73 m2. In patients with eGFR-EPI ≥ 60 ml/min*1.73 m2 vs eGFR-EPI < 60 ml/
min*1.73 m2: primary outcome-free time: 39.13 ± 19.22 months vs 34.85 ± 20.36 months, P = 0.18; HR: 0.12(0.06–0.23), P < 0.01; c Solid lines: urine 
protein ≥ 4 g/24 h, dashed lines: urine protein < 4 g/24 h. In patients with urine protein < 4 g/24 h vs urine protein ≥ 4 g/24 h: primary outcome-free 
time: 42.14 ± 19.37 months vs 35.04 ± 18.67 months, P < 0.01; HR: 3.89(1.18–12.79), P = 0.03; HR: 2.35(1.19–4.65), P = 0.01. d Solid lines: ≥ 65 years, 
dashed lines: < 65 years. In patients aged < 65 years vs ≥ 65 years: primary outcome-free time: months 39.24 ± 19.17 vs 37.04 ± 19.90 months, 
P = 0.32; HR: 6.15(3.12–12.14), P < 0.01; Upro urine protein
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risk factors of adverse outcome in 439 IMN patients by 
Cox proportional hazards model and validated by boot-
strap resampling analysis. Then we developed a risk score 
based on the 3 independent risk factors (age, eGFR and 
proteinuria) retained in the final Cox multivariate model. 
The risk score showed a good discriminating based on 
ROC curve. One unit increasing of the risk score was 
associated with 2.57 (1.97–3.36) fold increasing risk of 
primary outcome. To our knowledge, this is the first risk 
prediction tool based on baseline parameters that has 
been proposed for risk stratification in IMN patients and 
is helpful to improve clinical practices.
In our study, we found that age, eGFR and proteinu-
ria were 3 independent risk factors for unfavorable out-
come in IMN patients. The associations between age 
and ESRD in IMN patients was controversial based 
on previous studies. Shiiki et  al. [3] enrolled 949 Japa-
nese IMN patients and found that male gender, older 
age (≥ 60  years), higher serum creatinine concentra-
tion (≥ 1.5  mg/dl) and tubulointerstitial changes were 
Table 2 Cox proportional hazards ratio model of primary outcomes
Univariate analysis HR 
(95% CI)
P Multivariate analysis 
HR (95% CI)
P HR (95% CI) 
from Bootstrap 
analysis
P
Age (years) 1.09 (1.05–1.12) < 0.01 1.04 (1.003–1.08) 0.04 1.04 (1.01–1.08) 0.01
Female 0.62 (0.31–1.21) 0.16 – – – –
Albumin (g/l) 0.90 (0.85–0.95) < 0.01 – – – –
Proteinuria (g/24 h) 1.14 (1.06–1.21) < 0.01 1.09 (1.01–1.18) 0.03 1.09 (1.02–1.16) < 0.01
eGFR (ml/min/1.73 m2) 0.96 (0.95–0.97) < 0.01 0.97 (0.96–0.99) < 0.01 0.97 (0.96–0.99) < 0.01
Microscopic hematuria 0.78 (0.40–1.50) 0.45 – – – –
Triglyceride (mmol/l) 1.16 (0.97–1.39) 0.11
Cholesterol (mmol/l) 1.06 (0.93 ~ 1.22) 0.39 – – – –
Uric acid (μmol/l) 1.00 (0.99–1.01) 0.20 – – – –
Serum PLA2R antibody (RU/l) 1.00 (0.99–1.00) 0.28 – – – –
Pathological characteristics – – – –
 Stages I and II 1.00 (0.46–2.22) 0.99 – – – –
 ≥ 50% interstitial fibrosis 6.12 (2.54–14.73) < 0.01 – – – –
 PLA2R staining positive 26.08 (0.00–3 × 106) 0.59 – – – –
 IgG1 positive 0.99 (0.11–9.50) 0.99 – –
 IgG4 positive 0.40 (0.04–3.63) 0.40 – –
a b c
Fig. 2 Comparison of ROC curves, comparison of risk scores and survival curve for primary outcomes (a). Red line: Risk score; yellow line: eGFR-EPI; 
blue line: age; green line: proteinuria. Risk score AUC: 0.83 (95% CI 0.76–0.90); age AUC: 0.79 (95% CI 0.72–0.86), eGFR-EPI AUC: 0.81(95% CI 0.73–0.89) 
and proteinuria AUC: 0.69(95% CI 0.61–0.77) (b).Comparison of risk scores between patients with and without primary outcome (− 0.43 vs 1.37, 
P < 0.01). c Survival curve and Kaplan–Meier analysis for primary outcomes by risk score: high risk score vs low risk score: HR: 5.97, 95% CI 2.32–15.35 
(cut-off value: − 0.29). RS risk score
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associated with ESRD. However, no correlation was 
found between age and renal progression in Zent’s study 
[14]. He found although the mortality rate was higher, 
the ESRD rate was similar in elderly IMN patients than 
in young patients. It’s probably due to the competing risk 
of death and renal progression that masked the effect 
of age on renal outcome. Our study confirmed the cor-
relation between age and a combined outcome consist-
ing of renal function progression, ESRD and death. The 
associations between creatinine, proteinuria and inferior 
renal outcome in IMN patients were reported by several 
studies [8, 18]. In our study, we validated these findings 
in Asian population by using eGFR-EPI instead of cre-
atinine which is a better way in evaluating baseline renal 
function.
In our study, we did not validate the correlations 
between baseline serum anti-PLA2R antibody levels, 
renal PLA2R antigen and adverse outcomes in IMN 
patients. Kanigerchela et al. [19] found that high level of 
PLA2R antibody was correlated to disease activity and a 
higher risk for renal function deterioration based a study 
of 90 IMN patients. More recently, studies [9, 10] sug-
gested that dynamic measurement of serum anti-PLA2R 
antibodies was helpful to predict treatment response and 
relapses. Considering the limited number of patients 
with serum anti-PLA2R antibody and renal PLA2R anti-
gen measurements in our study, a more extended study is 
needed to draw further conclusions.
Cattran et al. has proposed a predictive model of renal 
prognosis in IMN patients based on dynamic changes of 
proteinuria and creatinine [20–22]. This model need fol-
low up patients for a period of time before the risk strati-
fication. In our study, we constructed a risk predicting 
tool based on baseline parameters, which can be directly 
applied into newly diagnosed IMN patients. The risk 
score showed a good discrimination based on ROC curve 
and discriminative slope between IMN patients with or 
without primary outcome. Thus, our risk score will be 
useful for clinicians to perform risk stratification for IMN 
patients.
Our study has several limitations. An external cohort of 
more ethnically diversified patients is needed for further 
validation. In addition, our study was based on a retro-
spective review of IMN patients, which needed to be fur-
ther evaluated in a prospective cohort.
Conclusion
Our study indicated that older IMN patients with lower 
eGFR and heavier proteinuria at the time of renal biopsy 
were at a higher risk for having adverse outcomes. A new 
risk score based on these three variables provides clini-
cians an effective tool for risk stratification.
Additional file
Additional file 1: Table S1. Baseline characteristics of different grades 
of IMN patients. Table S2. Hazards proportional assumption test by COX 
time-dependant covariates.
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